pharmaphorum

AUGUST 21, 2022

Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was held up by the regulator. Axsome acquired rights to the product in May, and reported almost $9 million in sales in the second quarter. Photo by Sydney Sims on Unsplash.

Drugs 98

Drugs FDA Approval Production Marketing 98

XTalks

AUGUST 31, 2022

In this episode, Ayesha discussed the FDA approval of Axsome Therapeutics’ rapid-acting oral treatment Auvelity for the treatment of major depressive disorder (MDD). Hear more about the therapy, some of the setbacks bluebird has had to face on the road to its approval and why the treatment has a steep price tag. Bluebird’s $2.8M

Gene Therapy 52

Gene Therapy FDA Approval Life Science Gene 52

pharmaphorum

NOVEMBER 24, 2022

One issue has been the cost of the drug, with health technology assessment agency NICE in the UK and the ICER organisation in the US both concluding its price tag means it is not a cost-effective option for health systems. The post J&J builds case for antidepressant Spravato with head-to-head trial appeared first on.

Trials 52

Trials Sales Drugs Marketing 52